A 68-year-old woman with hepatic cirrhosis (Child-Pugh class B) and portal hypertension requires emergency surgery for perforated diverticulitis. During anesthesia planning, the anesthesiologist must select agents considering her hepatic dysfunction. Analyze which anesthetic combination would be most appropriate for induction and maintenance.
Q2
A 19-year-old man with juvenile myoclonic epilepsy controlled on levetiracetam for 2 years presents with irritability, depression, and suicidal ideation that began 3 weeks ago. He has no prior psychiatric history. His seizures are well-controlled with no breakthrough events. Which modification to his treatment regimen is most appropriate?
Q3
A 42-year-old man with refractory status epilepticus has failed treatment with lorazepam, phenytoin, and valproic acid. He remains unconscious with ongoing seizure activity on continuous EEG monitoring. He has chronic kidney disease with GFR 25 mL/min/1.73m². Blood pressure is 88/52 mmHg requiring vasopressor support. Evaluate the most appropriate next pharmacologic intervention.
Q4
A 55-year-old man undergoing general anesthesia for coronary artery bypass grafting receives rocuronium for muscle relaxation. At the end of surgery, neostigmine is administered for reversal, but the patient remains apneic with no response to nerve stimulation. His brother had a similar prolonged paralysis after surgery. Dibucaine number testing shows 25% inhibition (normal: 80%). What is the underlying mechanism?
Q5
A 25-year-old woman with bipolar disorder well-controlled on valproic acid presents for preconception counseling. She has been seizure-free for 2 years and wants to become pregnant. Her psychiatrist is concerned about mood destabilization if medication is changed. Analyze the risk-benefit profile and determine the most appropriate management strategy.
Q6
A 34-year-old pregnant woman at 32 weeks gestation with severe preeclampsia is started on magnesium sulfate for seizure prophylaxis. After 6 hours, she becomes lethargic with decreased deep tendon reflexes and a respiratory rate of 8/min. Serum magnesium level is 14 mEq/L (therapeutic: 4-8 mEq/L). What is the most appropriate immediate intervention?
Q7
A 62-year-old woman with a history of malignant hyperthermia is scheduled for emergency cholecystectomy. During anesthesia induction with propofol and rocuronium, she develops muscle rigidity, hyperthermia to 40°C (104°F), tachycardia to 130/min, and hypercarbia. End-tidal CO2 is 68 mmHg. Serum potassium is 6.8 mEq/L and CK is 12,000 U/L. Which combination of interventions should be prioritized?
Q8
A 5-year-old boy with absence seizures characterized by brief staring spells 20-30 times daily is being evaluated for treatment. EEG shows 3-Hz spike-and-wave discharges. His mother is concerned about side effects affecting his school performance. Which medication is most appropriate as first-line therapy?
Q9
A 45-year-old man with complex partial seizures controlled on carbamazepine for 3 years presents with new-onset ataxia, diplopia, and confusion. His wife reports he recently started taking clarithromycin for pneumonia. Serum carbamazepine level is 18 mcg/mL (therapeutic range: 4-12 mcg/mL). What is the most appropriate immediate management?
Q10
A 28-year-old woman with newly diagnosed generalized tonic-clonic seizures is started on phenytoin. Two weeks later, she develops a maculopapular rash, fever to 39°C (102.2°F), facial edema, and cervical lymphadenopathy. Laboratory studies show eosinophilia and elevated liver transaminases (AST 245 U/L, ALT 280 U/L). Which mechanism best explains this patient's presentation?
CNS drugs (antiepileptics, anesthetics) US Medical PG Practice Questions and MCQs
Question 1: A 68-year-old woman with hepatic cirrhosis (Child-Pugh class B) and portal hypertension requires emergency surgery for perforated diverticulitis. During anesthesia planning, the anesthesiologist must select agents considering her hepatic dysfunction. Analyze which anesthetic combination would be most appropriate for induction and maintenance.
A. Etomidate for induction, sevoflurane for maintenance (Correct Answer)
B. Ketamine for induction, desflurane for maintenance
C. Propofol for induction, halothane for maintenance
D. Midazolam for induction, enflurane for maintenance
E. Thiopental for induction, isoflurane for maintenance
Explanation: ***Etomidate for induction, sevoflurane for maintenance***
- **Etomidate** is the preferred induction agent for patients with **Child-Pugh B** cirrhosis because it provides excellent **hemodynamic stability** and minimizes the risk of hypotension in patients with portal hypertension.
- **Sevoflurane** has a low rate of hepatic metabolism (2-5%) and does not significantly decrease **hepatic blood flow**, making it safer for maintenance in patients with liver dysfunction.
*Ketamine for induction, desflurane for maintenance*
- While **ketamine** maintains blood pressure, it can increase **myocardial oxygen demand** and may lead to unpredictable recovery in patients with impaired hepatic clearance.
- **Desflurane** is acceptable but can cause **sympathetic surge** and airway irritability, which may be less ideal than sevoflurane in an emergency surgical setting.
*Propofol for induction, halothane for maintenance*
- **Propofol** can cause significant **hypotension** and vasodilation, which may worsen the hemodynamic state of a patient with **cirrhosis** and portal hypertension.
- **Halothane** is strictly contraindicated due to the high risk of **halothane hepatitis** and its significant reduction in hepatic blood flow.
*Midazolam for induction, enflurane for maintenance*
- **Midazolam** is primarily metabolized by the liver, and its effects are significantly **prolonged** in patients with hepatic failure, leading to delayed emergence.
- **Enflurane** has a higher metabolic rate than sevoflurane and carries a theoretical risk of **nephrotoxicity** and mild hepatotoxicity.
*Thiopental for induction, isoflurane for maintenance*
- **Thiopental** relies on hepatic metabolism for clearance and can cause **cardiovascular depression** and hypotension during induction.
- While **isoflurane** is relatively safe for the liver, the combination with thiopental is less ideal than the etomidate-sevoflurane profile for **hemodynamic stability**.
Question 2: A 19-year-old man with juvenile myoclonic epilepsy controlled on levetiracetam for 2 years presents with irritability, depression, and suicidal ideation that began 3 weeks ago. He has no prior psychiatric history. His seizures are well-controlled with no breakthrough events. Which modification to his treatment regimen is most appropriate?
A. Continue levetiracetam and add an SSRI antidepressant
B. Increase levetiracetam dose to improve seizure control
C. Transition to valproic acid with psychiatric monitoring
D. Add lamotrigine while tapering levetiracetam (Correct Answer)
E. Discontinue levetiracetam immediately and start topiramate
Explanation: ***Add lamotrigine while tapering levetiracetam***
- **Levetiracetam** is well-known for **neuropsychiatric side effects**, including irritability, depression, and **suicidal ideation**, which necessitates drug discontinuation if these symptoms arise.
- **Lamotrigine** is an effective alternative for **juvenile myoclonic epilepsy (JME)** and offers **mood-stabilizing** benefits, making it the most appropriate replacement in this clinical scenario.
*Continue levetiracetam and add an SSRI antidepressant*
- Adding an **SSRI** treats the symptom rather than removing the causative agent, potentially exposing the patient to unnecessary polypharmacy and continued **drug-induced psychiatric distress**.
- The most direct and safest management for **medication-induced psychosis or depression** is the removal of the offending agent whenever a viable alternative exists.
*Increase levetiracetam dose to improve seizure control*
- The patient's seizures are already **well-controlled**, and increasing the dose would likely **exacerbate the neuropsychiatric toxicity** and suicidal ideation.
- Dose escalation is contraindicated when a patient is already experiencing significant **behavioral adverse effects** from the current dose.
*Transition to valproic acid with psychiatric monitoring*
- **Valproic acid** is highly effective for JME but is often avoided in young patients due to long-term risks like **metabolic side effects**, weight gain, and potential **teratogenicity** in future family planning.
- While effective, **lamotrigine** is generally preferred over valproate in this context due to a more favorable **side-effect profile** regarding weight and mood.
*Discontinue levetiracetam immediately and start topiramate*
- **Immediate discontinuation** of an antiepileptic drug (AED) significantly increases the risk of **status epilepticus** or breakthrough seizures; tapering is mandatory.
- **Topiramate** is less ideal for this patient as it can also cause **cognitive slowing** and may worsen certain psychiatric or mood disturbances.
Question 3: A 42-year-old man with refractory status epilepticus has failed treatment with lorazepam, phenytoin, and valproic acid. He remains unconscious with ongoing seizure activity on continuous EEG monitoring. He has chronic kidney disease with GFR 25 mL/min/1.73m². Blood pressure is 88/52 mmHg requiring vasopressor support. Evaluate the most appropriate next pharmacologic intervention.
A. Initiate propofol infusion titrated to EEG burst suppression
B. Load with additional phenytoin to achieve higher serum levels
C. Start ketamine infusion with hemodynamic monitoring (Correct Answer)
D. Administer midazolam bolus followed by continuous infusion
E. Begin pentobarbital coma with invasive monitoring
Explanation: ***Start ketamine infusion with hemodynamic monitoring***
- **Ketamine** is an **NMDA receptor antagonist** that is effective in **refractory status epilepticus** where GABAergic receptors have become internalized or downregulated.
- It provides beneficial **hemodynamic stability** or mild stimulation, making it the safest choice for this patient who is currently **hypotensive (88/52 mmHg)** and on vasopressors.
*Initiate propofol infusion titrated to EEG burst suppression*
- **Propofol** is a potent anesthetic for seizure control but frequently causes **hypotension**, which would exacerbate this patient's unstable hemodynamic status.
- Prolonged use carries the risk of **Propofol Infusion Syndrome (PRIS)**, and its cardiovascular effects are less desirable than ketamine in this scenario.
*Load with additional phenytoin to achieve higher serum levels*
- The patient has already failed **standard loading doses** of phenytoin; escalating levels beyond the therapeutic window increases the risk of **cardiac arrhythmias** and neurotoxicity.
- Phenytoin is ineffective for stopping ongoing **refractory seizure activity** when initial management has already failed to achieve clinical or EEG control.
*Administer midazolam bolus followed by continuous infusion*
- While midazolam is a standard third-line agent, it has already been preceded by **lorazepam failure**, suggesting resistance to **GABA-a receptor** agonism.
- High-dose infusions can cause **respiratory depression** and may worsen the patient's existing **hypotension**.
*Begin pentobarbital coma with invasive monitoring*
- **Pentobarbital** is a highly effective antiepileptic but is a potent **myocardial depressant** and peripheral vasodilator that would likely cause severe cardiovascular collapse in this patient.
- It has a long half-life and carries a high risk of **accumulation**, especially in the setting of multiorgan failure, making recovery assessment difficult.
Question 4: A 55-year-old man undergoing general anesthesia for coronary artery bypass grafting receives rocuronium for muscle relaxation. At the end of surgery, neostigmine is administered for reversal, but the patient remains apneic with no response to nerve stimulation. His brother had a similar prolonged paralysis after surgery. Dibucaine number testing shows 25% inhibition (normal: 80%). What is the underlying mechanism?
A. Rocuronium overdose requiring additional neostigmine
B. Atypical plasma cholinesterase with decreased metabolism (Correct Answer)
C. Neostigmine resistance due to receptor mutation
D. Hypermagnesemia potentiating neuromuscular blockade
E. Malignant hyperthermia with persistent muscle rigidity
Explanation: ***Atypical plasma cholinesterase with decreased metabolism***
- The patient exhibits **prolonged paralysis** and a low **dibucaine number** (20-25%), which is diagnostic for **pseudocholinesterase deficiency**, an autosomal recessive condition.
- This genetic variant results in an inability to metabolize drugs like **succinylcholine** or **mivacurium**, leading to extended apnea and the need for prolonged mechanical ventilation.
*Rocuronium overdose requiring additional neostigmine*
- While **rocuronium** is a non-depolarizing blocker, it is cleared by the liver and kidneys, not **plasma cholinesterase**, making the dibucaine test irrelevant.
- Increasing **neostigmine** in the setting of extreme blockade can potentially worsen respiratory distress or cause a **cholinergic crisis** without reversing the underlying genetic metabolic deficit.
*Neostigmine resistance due to receptor mutation*
- Resistance to **acetylcholinesterase inhibitors** typically involves issues at the **nicotinic acetylcholine receptor**, which does not align with a low **dibucaine number**.
- This mechanism would not explain why a patient's family member also experienced **prolonged paralysis** following general anesthesia.
*Hypermagnesemia potentiating neuromuscular blockade*
- High levels of **magnesium** can inhibit calcium entry into presynaptic terminals, but this is an electrolyte imbalance, not a **hereditary** metabolic disorder.
- **Hypermagnesemia** does not affect the **dibucaine number**, which specifically measures the quality of plasma enzyme function.
*Malignant hyperthermia with persistent muscle rigidity*
- **Malignant hyperthermia** presents with life-threatening **hyperthermia**, tachycardia, and **muscle rigidity**, rather than the flaccid paralysis seen in this patient.
- It is caused by a mutation in the **ryanodine receptor (RYR1)** and is triggered by volatile anesthetics or succinylcholine, but is unrelated to **pseudocholinesterase activity**.
Question 5: A 25-year-old woman with bipolar disorder well-controlled on valproic acid presents for preconception counseling. She has been seizure-free for 2 years and wants to become pregnant. Her psychiatrist is concerned about mood destabilization if medication is changed. Analyze the risk-benefit profile and determine the most appropriate management strategy.
A. Add levetiracetam to valproic acid and taper valproic acid postpartum
B. Continue valproic acid with high-dose folic acid supplementation
C. Switch to lamotrigine before conception with close monitoring (Correct Answer)
D. Discontinue all medications during pregnancy attempt
E. Continue valproic acid and plan for prenatal diagnostic testing
Explanation: ***Switch to lamotrigine before conception with close monitoring***
- **Valproic acid** is highly teratogenic, associated with **neural tube defects**, craniofacial abnormalities, and significant **neurodevelopmental delays** (lower IQ).
- **Lamotrigine** is a preferred alternative in pregnancy for both bipolar disorder and seizures due to its significantly lower risk of **major congenital malformations**.
*Add levetiracetam to valproic acid and taper valproic acid postpartum*
- Adding another drug increases the total drug burden and does not eliminate the severe **teratogenic exposure** during the critical first trimester.
- Tapering **valproic acid** postpartum is too late to prevent **organogenesis** defects and neurodevelopmental impacts that occur in utero.
*Continue valproic acid with high-dose folic acid supplementation*
- While **folic acid** (4-5 mg) is recommended for women on AEDs, it does not fully mitigate the 10% risk of birth defects associated with **valproate**.
- Continuing valproate is generally avoided unless all other medications have failed, due to its status as the most **teratogenic** common anticonvulsant.
*Discontinue all medications during pregnancy attempt*
- Complete discontinuation poses a high risk of **bipolar relapse** and breakthrough medical instability, which can harm both mother and fetus.
- A managed transition to a **safer monotherapy** is standard of care rather than total withdrawal of psychiatric stabilization.
*Continue valproic acid and plan for prenatal diagnostic testing*
- **Prenatal testing** (like alpha-fetoprotein or ultrasound) only identifies defects after they have occurred; it does not prevent the **teratogenicity**.
- Relying on diagnostics rather than prevention ignores the high clinical risk of **cognitive impairment** which cannot be detected via standard prenatal imaging.
Question 6: A 34-year-old pregnant woman at 32 weeks gestation with severe preeclampsia is started on magnesium sulfate for seizure prophylaxis. After 6 hours, she becomes lethargic with decreased deep tendon reflexes and a respiratory rate of 8/min. Serum magnesium level is 14 mEq/L (therapeutic: 4-8 mEq/L). What is the most appropriate immediate intervention?
A. Endotracheal intubation and mechanical ventilation
B. Immediate hemodialysis
C. Intravenous calcium gluconate (Correct Answer)
D. Intravenous furosemide
E. Discontinue magnesium and observe
Explanation: ***Intravenous calcium gluconate***
- **Calcium gluconate** (or calcium chloride) is the immediate antidote for **magnesium toxicity** as calcium ions directly antagonize the neuromuscular and cardiac effects of magnesium.
- This patient exhibits classic signs of toxicity: loss of **deep tendon reflexes** (7-10 mEq/L), **respiratory depression** (10-13 mEq/L), and serum levels well above the therapeutic range.
*Endotracheal intubation and mechanical ventilation*
- While ensuring a patent airway is vital, the first step in pharmacological toxicity is administering the **specific antidote** to reverse the cause of hypoventilation.
- This intervention may be necessary if the patient does not respond to **calcium gluconate** or goes into respiratory arrest.
*Immediate hemodialysis*
- **Hemodialysis** is an effective way to remove magnesium but is reserved for severe toxicity in patients with **renal failure** or those who are hemodynamically unstable.
- It is not the most appropriate **immediate** first-line step when medicinal antagonism is available.
*Intravenous furosemide*
- **Furosemide** can enhance the renal excretion of magnesium in patients with normal kidney function by inhibiting reabsorption in the **loop of Henle**.
- It is a supportive measure and is far too slow compared to the rapid action of **intravenous calcium** in an acute emergency.
*Discontinue magnesium and observe*
- While **stopping the infusion** is a necessary step, simply observing a patient with a respiratory rate of 8/min and severe toxicity is insufficient.
- Failure to actively reverse the toxicity with **calcium** could lead to **cardiac arrest** or fatal respiratory failure.
Question 7: A 62-year-old woman with a history of malignant hyperthermia is scheduled for emergency cholecystectomy. During anesthesia induction with propofol and rocuronium, she develops muscle rigidity, hyperthermia to 40°C (104°F), tachycardia to 130/min, and hypercarbia. End-tidal CO2 is 68 mmHg. Serum potassium is 6.8 mEq/L and CK is 12,000 U/L. Which combination of interventions should be prioritized?
A. Discontinue anesthesia, administer dantrolene, hyperventilate, and cool patient (Correct Answer)
B. Continue surgery with non-triggering agents and administer calcium gluconate
C. Administer succinylcholine for muscle paralysis and increase volatile anesthetic
D. Give intravenous bicarbonate and insulin with glucose for hyperkalemia
E. Initiate cardiopulmonary bypass and therapeutic hypothermia
Explanation: ***Discontinue anesthesia, administer dantrolene, hyperventilate, and cool patient***
- **Malignant hyperthermia** is a hypermetabolic emergency characterized by **hypercarbia**, muscle rigidity, and **hyperthermia**; the immediate priority is halting the trigger and administering **dantrolene**.
- **Dantrolene** acts by inhibiting the **ryanodine receptor (RYR1)**, which prevents further calcium release from the sarcoplasmic reticulum into the myoplasm.
*Continue surgery with non-triggering agents and administer calcium gluconate*
- Surgery should be **aborted or finished rapidly** if feasible to focus all efforts on aggressive resuscitation and stabilization.
- While **calcium gluconate** protects the heart during hyperkalemia, it is a supportive measure and does not address the underlying **RYR1-mediated** crisis.
*Administer succinylcholine for muscle paralysis and increase volatile anesthetic*
- **Succinylcholine** and **volatile anesthetics** are the primary triggers of malignant hyperthermia and would worsen the muscle rigidity and metabolic storm.
- Increasing volatile anesthetics would lead to fatal **rhabdomyolysis**, extreme **hyperkalemia**, and cardiac arrest in a susceptible patient.
*Give intravenous bicarbonate and insulin with glucose for hyperkalemia*
- These are necessary secondary treatments for **metabolic acidosis** and **electrolyte imbalance**, but they are not the definitive first-line priority.
- Priority must be given to **dantrolene** and metabolic stabilization; treating hyperkalemia alone will not stop the **hypermetabolic state**.
*Initiate cardiopulmonary bypass and therapeutic hypothermia*
- **Cardiopulmonary bypass** is an invasive measure reserved for cases of refractory cardiac arrest and is not standard initial management.
- **Active cooling** should be performed using IV cold saline and surface cooling, not necessarily the extreme of therapeutic hypothermia via bypass.
Question 8: A 5-year-old boy with absence seizures characterized by brief staring spells 20-30 times daily is being evaluated for treatment. EEG shows 3-Hz spike-and-wave discharges. His mother is concerned about side effects affecting his school performance. Which medication is most appropriate as first-line therapy?
A. Phenytoin
B. Carbamazepine
C. Ethosuximide (Correct Answer)
D. Phenobarbital
E. Gabapentin
Explanation: ***Ethosuximide***
- **Ethosuximide** is the preferred first-line therapy for **absence seizures** because it specifically inhibits **T-type calcium channels** in the thalamus.
- It is favored in school-aged children due to its high efficacy and significantly **fewer cognitive side effects** compared to other anticonvulsants.
*Phenytoin*
- This agent is primarily used for **focal** and **generalized tonic-clonic seizures** but is ineffective against absence seizures.
- Use of **phenytoin** in a patient with absence seizures can potentially **exacerbate** the frequency and severity of the staring spells.
*Carbamazepine*
- Primarily indicated for **focal seizures** and trigeminal neuralgia, it is contraindicated in patients with primary generalized epilepsies.
- **Carbamazepine** is known to **worsen absence seizures** and should be avoided when 3-Hz spike-and-wave discharges are present.
*Phenobarbital*
- **Phenobarbital** is a sedative-hypnotic used for neonatal seizures and status epilepticus but is not a first-line agent for absence epilepsy.
- Its significant side effects, including **sedation** and **behavioral changes**, would negatively impact the patient's **school performance**.
*Gabapentin*
- Used mainly for **neuropathic pain** and as an adjunct for focal seizures, it has no role in the management of absence epilepsy.
- Similar to carbamazepine, **gabapentin** may potentially **aggravate seizure activity** in children with typical absence seizures.
Question 9: A 45-year-old man with complex partial seizures controlled on carbamazepine for 3 years presents with new-onset ataxia, diplopia, and confusion. His wife reports he recently started taking clarithromycin for pneumonia. Serum carbamazepine level is 18 mcg/mL (therapeutic range: 4-12 mcg/mL). What is the most appropriate immediate management?
A. Continue current medications and monitor symptoms
B. Discontinue carbamazepine and start levetiracetam
C. Hold carbamazepine temporarily and discontinue clarithromycin (Correct Answer)
D. Reduce carbamazepine dose by 50% and continue clarithromycin
E. Add activated charcoal for carbamazepine elimination
Explanation: ***Hold carbamazepine temporarily and discontinue clarithromycin***
- The patient exhibits classic **carbamazepine toxicity** (ataxia, diplopia, confusion) caused by **clarithromycin**, a potent **CYP3A4 inhibitor** that prevents carbamazepine metabolism.
- Immediate management requires **holding carbamazepine** to allow serum levels to fall and removing the **offending drug** (clarithromycin) to normalize metabolic clearance.
*Continue current medications and monitor symptoms*
- Continuing these medications is dangerous as **carbamazepine levels** are already in the **toxic range** (18 mcg/mL).
- Persistent toxicity can lead to severe neurological deterioration or **seizures** if the drug interaction is not addressed.
*Discontinue carbamazepine and start levetiracetam*
- Completely discontinuing carbamazepine and switching agents is an **extreme measures** for a temporary, drug-induced interaction.
- It is more appropriate to manage the **acute toxicity** and then adjust the dose or change the **interacting antibiotic**.
*Reduce carbamazepine dose by 50% and continue clarithromycin*
- Reducing the dose while keeping a potent **enzyme inhibitor** onboard is unpredictable and may not rapidly resolve the **neurological symptoms**.
- The priority is to stop the inhibitor and allow the patient to recover from the **elevated serum concentration**.
*Add activated charcoal for carbamazepine elimination*
- **Activated charcoal** is typically reserved for acute **overdose ingestions** occurring within 1-2 hours of presentation.
- This patient has chronic accumulation due to **metabolic inhibition**, where systemic removal or drug cessation is the standard of care.
Question 10: A 28-year-old woman with newly diagnosed generalized tonic-clonic seizures is started on phenytoin. Two weeks later, she develops a maculopapular rash, fever to 39°C (102.2°F), facial edema, and cervical lymphadenopathy. Laboratory studies show eosinophilia and elevated liver transaminases (AST 245 U/L, ALT 280 U/L). Which mechanism best explains this patient's presentation?
A. Type I hypersensitivity reaction to phenytoin
B. Type IV hypersensitivity reaction with multi-organ involvement (Correct Answer)
C. Phenytoin-induced lupus erythematosus
D. Cytochrome P450 enzyme induction causing drug interaction
E. Direct hepatotoxic effect of phenytoin metabolites
Explanation: ***Type IV hypersensitivity reaction with multi-organ involvement***
- This patient presents with **DRESS syndrome** (Drug Reaction with Eosinophilia and Systemic Symptoms), characterized by a **delayed Type IV T-cell mediated** hypersensitivity to drugs like **phenytoin**.
- Key diagnostic features include the 2-8 week latency, **fever**, **eosinophilia**, **facial edema**, and internal organ involvement such as **hepatitis**.
*Type I hypersensitivity reaction to phenytoin*
- This typically presents as **urticaria** or **anaphylaxis** within minutes to hours of drug exposure via **IgE-mediated** mast cell degranulation.
- It does not explain the **eosinophilia**, significant **liver enzyme elevation**, or the delayed two-week onset seen here.
*Phenytoin-induced lupus erythematosus*
- Drug-induced lupus (DILE) usually presents with **arthralgia**, **myalgia**, and serositis, and is associated with **anti-histone antibodies**.
- While phenytoin can cause DILE, it characteristically lacks the **eosinophilia** and profound **facial edema** typical of DRESS.
*Cytochrome P450 enzyme induction causing drug interaction*
- Phenytoin is a potent **CYP450 inducer**, which typically results in decreased efficacy of co-administered drugs like **warfarin** or **oral contraceptives**.
- This metabolic induction does not cause **hypersensitivity** symptoms like **rash**, **lymphadenopathy**, or **eosinophilia**.
*Direct hepatotoxic effect of phenytoin metabolites*
- While phenytoin can cause liver injury, the systemic constellation of **rash**, **fever**, and **eosinophilia** signifies an **immunological reaction** rather than simple dose-dependent toxicity.
- The damage in DRESS is primarily mediated by **activated T-lymphocytes** rather than direct chemical toxicosis of the hepatocytes.
